Enrollmi.ru, a resident of the Skolkovo Foundation Biomedical Technology Cluster, has provided its technology platform for conducting an observational study in Russia of patients with blood system diseases and the new COVID-19 coronavirus infection.
The observational study CHRONOS19 (NCT04422470) is carried out by the National Medical Research Center for Hematology (NRC Hematology) of the Ministry of Health of Russia together with several regional hematological clinics. The Oncology Research Support Foundation (RakFond) and the Skolkovo resident, Enrollmi.ru, also participate in the project. Enrollmi.ru, a technology platform for remote management of clinical and observational studies, will allow doctors in different cities of Russia to be united into a single research network. During the year, work can be carried out directly in the “red zone” in a paperless form and without the threat of the spread of infection.
Several recent studies have found that the presence of cancer worsens the prognosis in patients with a new coronavirus infection COVID-19. Patients with diseases of the blood system may have an increased risk of infection with the SARS-CoV-2 virus and a more severe course of the disease due to the nature of the underlying disease and the specific treatment that often suppresses the immune system. However, information on the course of COVID-19 in patients with hematologic diseases is currently limited.
The main goal of the CHRONOS19 study is to determine the course of the new coronavirus infection COVID-19 in patients with various hematological diseases. Experts hope that the results will allow in the near future to improve the treatment methods of this category of patients.
Valery Savchenko, director of the Hematology Research Center: “This study will combine the efforts of hematologists in several regions of Russia to help patients with blood system diseases during a pandemic. Today we need to learn to understand the features of a new infection in hematological patients so that in the future our patients receive the most effective treatment and tactically we are ready for such pandemics to occur. ”
Kristina Zakurdaeva, founder of the Cancer Foundation: “During a pandemic, it is very important not only to learn how to control the infection, but also not to miss the development of the underlying disease in hematological patients. Therefore, the ability to quickly obtain objective data on the course of the disease in especially vulnerable groups of patients is of great importance in order to determine the management tactics of these patients. The results of the study will lay the foundation for improving treatment outcomes for patients with diseases of the blood system and coronavirus infection. ”
Mikhail Getman, founder and head of Enrollmi.ru: “It is obvious that the new coronavirus infection COVID-19 will remain with people forever. Therefore, today, researchers around the world are sending the best forces to study and analyze the disease in all groups of patients. The results of the study are very necessary for those people who are courageously struggling with other serious ailments. We recognize the importance of this work and are pleased to provide our technological solutions for its implementation. ”
Larisa Kravchenko, project manager of the Skolkovo Foundation Biomedical Technology Cluster: “Because of the coronavirus pandemic, patients with hematologic diseases have new risks that have not been explored before. Therefore, the study of the characteristics of the course of the underlying disease in the new conditions is becoming one of the highest priorities for scientists. The electronic platform of the Skolkovo participant at Enrollmi.ru has proven its worth and makes it possible to conduct research completely remotely, eliminating the risks of infection for research participants. ”
The study will begin in June 2020 and will last about a year. About 200 patients with diseases of the blood system infected with the SARS-CoV-2 virus will take part in it. To join the study, you must send an email to firstname.lastname@example.org (Olga Aleksandrovna Gavrilina).
Federal State Budgetary Institution Scientific Research Center for Hematology of the Russian Ministry of Health is the largest scientific, clinical and educational center of hematology in the Russian Federation, an organization for the strategic development of healthcare in the fields of hematology, transfusiology and oncology. The scientific and clinical clinical units of the center carry out research at world and national levels in the fields of fundamental and applied hematology, biology, molecular genetics, transplant and transfusion immunology, biochemistry, mathematical modeling, pharmacology, bioinformatics and biostatistics. Annually, over 5,000 patients with hemoblastoses and other diseases of the blood system receive treatment at the Center; more than 1,500 surgical interventions are performed, of which more than 200 are performed on bone marrow and kidney transplantation. Website: http://blood.ru
Enrollmi.ru is a Russian technology company, a participant in the Skolkovo project, using a digital platform of its own design for the remote organization of clinical and observational studies in the field of life sciences. Enrollmi.ru technologies use exclusively Russian program code, provide a high level of data protection and allow for large-scale research throughout Russia, including in the context of an infectious disease pandemic. Website: https://enrollme.ru
Cancer Fund is a non-profit organization whose main objectives are to finance research and development of new methods and means of prevention, diagnosis and treatment of cancer, promote the development and improvement of research and scientific activities of research institutes, scientific centers, medical institutions of oncological profile or individual specialists in the field of oncology. The fund was founded in 2017 and operates in the Russian Federation. Website: https://www.rakfond.org
Skolkovo Foundation is a non-profit organization created on the initiative of the President of the Russian Federation in September 2010. The goal of the Fund is to create an ecosystem conducive to the development of entrepreneurship and research in the areas of: energy efficiency and energy conservation, nuclear, space, biomedical, strategic computer technologies and software. The Fund is entrusted with the management of the Skolkovo Innovation Center, whose activities are regulated by a special law that provides special economic conditions to startups that have undergone special external technological expertise (now there are more than 2,400 of them). In 2019, the revenue of Skolkovo participating companies amounted to 111.6 billion rubles, the total revenue over the 10 years of the project's existence reached 412.7 billion rubles. More than 35 thousand people work in startups. In total, more than 2900 developments and technological solutions have been patented. An important part of the Skolkovo ecosystem is a research university - the Skolkovo Institute of Science and Technology (Skoltech), created and functioning with the support of the Massachusetts Institute of Technology. The construction of the infrastructure of the IC Skolkovo at the expense of the federal budget has been completed (Technopark, University, Gymnasium, road and engineering infrastructure have been built). Over 750 thousand square meters were commissioned. m. objects.